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ABSTRACT: Wheat gluten confers superior baking quality to wheat based products but elicits a pro-inflammatory immune
response in patients with celiac disease. Transamidation of gluten by microbial transglutaminase (mTG) and tissue
transglutaminase (tTG) reduces the immunogenicity of gluten; however, little information is available on the minimal
modification sufficient to eliminate gliadin immunogenicity nor has the effectiveness of transamidation been studied with T-cell
clones from patients. Here we demonstrate that mTG can efficiently couple three different acyl-acceptor molecules, L-lysine,
glycine ethyl ester, and hydroxylamine, to gliadin peptides and protein. While all three acyl-acceptor molecules were cross-linked
to the same Q-residues, not all modifications were equally effective in silencing T-cell reactivity. Finally, we observed that tTG
can partially reverse the mTG-catalyzed transamidation by its isopeptidase activity. These results set the stage to determine the
impact of these modifications on the baking quality of gluten proteins and in vivo immunogenicity of such food products.
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■ INTRODUCTION
Celiac disease (CD) is a T-cell-mediated autoimmune enter-
opathy, induced by the ingestion of prolamins fromwheat, rye, or
barley, with an estimated worldwide prevalence of approximately
1%.1 CD has a strong genetic component as approximately 95%
of patients carry HLA (human leukocyte antigen)-DQ2
(A1*0501/B1*0201), while the remainder is usually HLA-
DQ8 (A1*0301/B1*0302) positive.2 This association is
explained by the observation that T-cell specific for gluten
peptides bound to either HLA-DQ2 or HLA-DQ8 are found in
patients with CD.3,4 At present, there is no effective treatment for
CD patients except a permanent life-long gluten free diet (GFD).
A number of gluten T-cell epitopes associated with HLA-DQ
receptors of CD have been identified.5 A highly antigenic 33-mer
peptide from α-gliadin is resistant to gastric and intestinal
proteolysis and contains six partially overlapping T-cell epitopes:
PFPQPQLPY (DQ2.5-glia-α1a), PYPQPQLPY (DQ2.5-glia-
α1b, two copies), and PQPQLPYPQ (DQ2.5-glia-α2, three
copies).6,7 It is well established that tissue transglutaminase
(tTG) plays a critical role in CD pathogenesis. Specifically, the
tTG mediated deamidation of Q → E strongly enhances the
binding of gluten epitopes to HLA-DQ2 or HLA-DQ8 and such
peptide-HLA-DQ complexes strongly activate gluten-specific T-
cell clones.8−10
Microbial transglutaminase (mTG) from Streptomyces mobar-
aensis is a food-grade transamidase and widely used in the food
industry. Similar to tTG, mTG can deamidate glutamine residues
to glutamic acid residues, resulting in gluten peptides with T-cell
stimulatory properties.11−14 In contrast mTG does not affect the
reactivity of gliadin-specific antibodies.15 Here, the in vitro
transamidation of Q by either tTG or mTG can prevent the
deamidation process induced by tTG present in the human
intestine. Indeed, previous studies indicated that selective
modification of glutamine residues present in toxic epitopes by
mTG transamidation using L-lysine or L-lysine methyl ester
prevented the deamidation process.16,17 Moreover, Elli et al.
found that the modification of gluten by tTG with L-lysine
inhibited the duodenal immunological effects on cultured
biopsies from CD patients.18 Additionally, gluten transamidated
by tTG and L-lysine methyl ester reduced the number of clinical
relapses in challenged patients but did not eradicate the
antigenicity of gluten.19 Transamidated gluten can be used to
produce bread with less immunoreactive gluten20 and recently,
Ribeiro et al. exploited n-butylamine and mTG to obtain wheat
flour with decreased CD toxic epitopes.21 Most importantly,
mTG has much lower deamidation activity as compared with
tTG22 and mTG is active with a variety of acyl-acceptor
molecules so that several additional acyl-acceptor molecules can
be used instead of lysine and link them to peptides or proteins of
interest.23,24
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Gluten has unique properties which make it highly suitable for
the preparation of high quality dough, which are tightly linked to
its characteristic amino acid composition dominated by high
glutamine content. Therefore, modification of such glutamines
by transamidation could have negative consequences.25 Minimal
modification is thus desirable; however, little information on the
minimal modification sufficient to eliminate gluten immunoge-
nicity is available. Therefore, we investigated whether apart from
lysine other acyl-acceptor molecules can also be used with mTG
to eliminate the T-cell stimulatory properties of gliadin peptides
and proteins. For this purpose we compared the effect of
transamidation with L-lysine (Lys), glycine ethyl ester (GEE),
and hydroxylamine (HA) as acyl-acceptor molecules.
■ MATERIALS AND METHODS
Synthetic Peptides and Chemicals. DQ2.5-glia-α1a (native form
LQPFPQPQLPYPQ and deamidated form LQPFPQPELPYAA),
DQ2.5-glia-α2 (native form PFPQPQLPYPQPQ and deamidated
form AAPQPELPYPQPQ), and deamidated 33-mer (LQLQPF
(PQPELPY)3 PQPQPF) peptides were synthesized by standard Fmoc
chemistry on a multiple peptide synthesizer (Syroll, MultiSynTech
GmbH, Witten, Germany). The native 33-mer peptide (LQLQPF
(PQPQLPY)3 PQPQPF) was synthesized by GL Biochem Ltd.
(Shanghai, China). Details on the HLA-DQ2 binding properties of
the gliadin peptides can be found in the reference Sollid et al.5 The purity
and integrity of the peptides was confirmed by reversed-phase high-
performance liquid chromatography (RP-HPLC) and mass spectrom-
etry. mTG from Streptomyces mobaraensis was donated by Jiangsu
Yiming Biological Products Co., Ltd. (Jiangsu, China) with a declared
activity of 1 000 units (U)/ g and has an amino sequence that is identical
to Ajinomoto transglutaminase. L-Lysine (Lys, >98%) was bought from
Sangon Biotech (Shanghai, China). Glycine ethyl ester hydrochloride
(GEE, >98%), hydroxylamine hydrochloride (HA, 98%), lysine methyl
ester (LME), and n-butylamine (BL, >99.5%) were from Sigma-Aldrich.
Gliadin, pepsin (3800 units/mg solid), trypsin (activity 10 000 BAEE
units/mg), and tTG from guinea pig liver (4 units/mg solid) were
purchased from Sigma-Aldrich. IMDM used in cell culture was obtained
from Lonza (BioWhittaker, Belgium). Other chemicals were of
analytical grade.
Modification of Peptides by mTG and tTG. In order to study the
effect of pH on the transamidation and deamidation reaction, the
experiments were performed according to a previous study with some
modifications.26 In preliminary experiments, we observed that the mTG
enzyme activity at pH 8.0 is lower than at pH 6.0, in agreement with
previous work.22 On the basis of these results and with the aim of
achieving optimal transmidation at both low and high pH, we choose to
use 0.13 U mTG at pH 8.0 and 0.50 U mTG at pH 6.0. All mTG
experiments were carried out in 200 mM HEPES buffer. For
determination of the effect of pH on transamidation 0.19 μmol of 33-
mer, 0.50 U mTG with either 40 μmol of Lys or 40 μmol of HA was
incubated in 1 mL of buffer at either pH 6.0, 7.0, or 8.0 for 1 h. To
determine the effect of the acyl-acceptor concentration on the
transamidation reaction 0.19 μmol of 33-mer, 0.13 U mTG and a
concentration range of GEE (0.16 μmol, 0.63 μmol, 2.50 μmol, 10 μmol,
or 40 μmol) was incubated in 1 mL of buffer at pH 6.0 for 1 h.
On the basis of previous work27 and the effect of the acyl-acceptor
concentration on the transamidation reaction, it was deduced that the
33-mer has three modification sites, whereas the DQ2.5-glia-α1a and
DQ2.5-glia-α2 have one modification site. Therefore, a 1:210 molar
ratio between the 33-mer peptide and acyl-acceptor molecule and a 1:70
molar ratio between DQ2.5-glia-α1a/DQ2.5-glia-α2 and acyl-acceptor
molecule was selected. As Lys has a pKa value that is substantially higher
as that of both GEE and HA,23 we choose to use pH 8.0 in the case of
Lys, pH 6.0 in the case of HA, and GEE for all further experiments. In
detail, 0.19 μmol of 33-mer, 0.50 U mTG, and 40 μmol of Lys was
incubated in 1 mL of reaction mixture at pH 8.0, while 0.19 μmol of 33-
mer, 0.13 U mTG, and 40 μmol of GEE/HA was incubated in 1 mL of
reaction mixture at pH 6.0. For DQ2.5-glia-α1a and DQ2.5-glia-α2, 0.57
μmol of peptide, 0.50 U mTG, and 40 μmol of Lys was incubated in a
final volume of 1 mL at pH 8.0, and 0.57 μmol of peptide, 0.13 U mTG,
and 40 μmol of GEE, HA, LME, or BL was incubated in a final volume of
1 mL at pH 6.0. For deamidation, 0.19 μmol of 33-mer peptide or 0.57
μmol of DQ2.5-glia-α1a/α2 and 0.50 UmTGwere mixed in 1 mL at pH
6.0, 7.0, or 8.0.
The reaction mixtures were preincubated for 5 min at 50 °C before
adding mTG. mTG treatment was carried out at 50 °C for 1 h, followed
by termination of the enzymatic reaction by heating at 85−90 °C for 10
min. Subsequently, in selected experiments, tTG treatment was
performed by incubating 50 μL of mTG-transamidated product with
15 μL of tTG (1 mg/mL) in a final volume of 65 μL at 37 °C, pH 6.5 for
16 h, in 200 mM HEPES buffer with 8 mM CaCl2.
Mass Spectrometry. Mass spectrometric analysis of the synthetic
gluten peptides before and after mTG and tTG-mTG treatment was
performed on a Bruker Microflex (matrix-assisted laser desorption
ionization-time-of-flight (MALDI TOF)) and a Thermo Fisher LTQ-
FT Ultra. For the MALDI TOF part, matrix solution (10 mg/mL α-
cyano-4-hydroxycinnamic acid in 50:50 acetonitrile/water with 0.2%
TFA) was prepared. Next, peptide solutions were mixed with 1 μL of
matrix solution on a 96 well target plate. Measurements were detected in
reflectron mode with acquisition mass range of 500−5000 Da. For
DQ2.5-glia-α1a, DQ2.5-glia-α2 peptides, and their modified forms,
measured average masses were corrected based on the mass of the
reference peptide (VNTPEHVVPYGLGSPSRS, monoisotopic mass
1895.96). Peptide Calibration Standard from Bruker was used to
calibrate the data of the 33-mer peptide and its modified forms.
For Fourier transform-ion cyclotron resonance (FT-ICR) mass
spectrometry, peptides were measured by tandem MS, equipped with a
nanoflow liquid chromatography 1100 HPLC system (Agilent
Technologies), as previously described.28 Peptides were trapped at 10
μL/min on a 1.5 cm column (100-μm i.d. ReproSil-Pur C18-AQ, 3 μm,
Dr. Maisch GmbH, Germany) and eluted to a 20 cm column (50-μm
ID; ReproSil-Pur C18-AQ, 3 μm) at 150 nL/min. The column was
developed with a 20 min gradient from 0 to 30% acetonitrile in 0.1%
formic acid. The end of the nanocolumn was drawn to a tip (i.d. about 5
μm), from which the eluent was sprayed into a LTQ-FT Ultra mass
spectrometer (Thermo Electron). The mass spectrometer was operated
in data-dependent mode, automatically switching betweenMS andMS/
MS acquisition. Full scan MS spectra were acquired in the FT-ICR with
a resolution of 25 000 at a target value of 3 000 000. The two most
intense ions were then isolated for accurate mass measurements by a
selected ion monitoring scan in FT-ICR with a resolution of 50 000 at a
target accumulation value of 50 000. The selected ions were then
fragmented in the linear ion trap using collision-induced dissociation at a
target value of 10 000. The tandem mass spectra of modified and
unmodified gliadin peptides were compared andmanually interpreted to
determine the site of modification.
Gliadin Preparation and Modification. For the purpose of
modification of gliadin in solution, a pepsin/trypsin digest of gliadin was
prepared as described previously with some modifications.29 First, 1 g of
gliadin was solubilized in 10 mL of 1M acetic acid and boiled for 10 min.
Subsequently, 10 mg of pepsin was added and the mixture was incubated
for 4 h at 37 °C followed by the adjustment of the pH to 7.8 with NaOH
and the addition of 10 mg of trypsin. Next, the mixture was incubated for
another 4 h at 25 °C. Finally, the mixture was dialyzed with water
(molecular weight cutoff, 14 kDa), followed by concentrating using 10
kDa centrifugal filter units. The protein concentration was determined
by a bicinchoninic acid (BCA) assay.
mTG treatment of the gliadin preparation was performed as follows:
1 mg of gliadin was mixed with 0.50 U mTG and 10 μmol, 40 μmol, or
160 μmol of Lys in a final volume of 1 mL at pH 8.0. For transamidation
with GEE and HA, 1 mg of gliadin, 0.13 U mTG and 10 μmol, 40 μmol
or 160 μmol acyl-acceptor molecules were mixed in a final volume of 1
mL at pH 6.0. For themTGmediated deamidation, the reaction solution
was prepared using 1 mg of gliadin and 0.50 U mTG.
The reaction mixtures were preincubated for 5 min at 50 °C before
adding mTG. mTG treatment was carried out at 50 °C for 1 h, followed
by termination of the enzymatic reaction by heating at 85−90 °C for 10
min. Subsequently, tTG treatment was performed by incubating 50 μL
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of mTG-transamidated product with 15 μL of tTG (1 mg/mL) in a final
volume of 65 μL at 37 °C, pH 6.5 for 16 h, in 200 mM HEPES buffer
with 8 mM CaCl2.
T-Cell Proliferation Assays. Proliferation assays were performed in
150 μL of IMDMmedium supplemented with 2mMglutamine and 10%
human serum in 96-well flat-bottom plates as previously described.30 In
brief, irradiated (3000 rad) HLA-DQ2-matched antigen-presenting cells
(105) were incubated with 50 μL of antigen for 2 h, followed by the
addition of 15 000 DQ2.5-glia-α1 or DQ2.5-glia-α2 specific T-cell
clones. All conditions were carried out in triplicate. mTG- and tTG-
Figure 1. Transamidation pattern of DQ2.5-glia-α1a, DQ2.5-glia-α2, and 33-mer peptide after modification using mTG and three different acyl-
acceptor molecules. (A) Effect of pH on 33-mer reaction induced by mTG in the presence of Lys. (B) Effect of pH on 33-mer reaction induced by mTG
in the presence of HA. (C) Effect of GEE concentration on 33-mer transamidation induced by mTG at pH 6.0. Molar ratio between the 33-mer peptide
and GEE is 1:0.84, 1:3.32, 1:13.16, 1:52.63, 1:210.53 as shown. (D) Transamidation pattern of 33-mer by mTG. As compared with native peptide, 33-
mer cross-linked to Lys, GEE, and HA resulted in a shift of 129 × 3 Da, 86 × 3 Da and 16 × 3 Da, corresponding to the addition of three Lys, GEE, and
HA groups, respectively. (E) Transamidation pattern of DQ2.5-glia-α1a by mTG. DQ2.5-glia-α1a presented 129 Da, 86 Da, and 16 Da shift responding
to the addition of a single Lys, GEE, andHA group. (F) Transamidation pattern of DQ2.5-glia-α2 bymTG. DQ2.5-glia-α2 presented 129Da, 86 Da, and
16 Da shift responding to the addition of a single Lys, GEE, and HA group. Monoisotopic mass are shown throughout.
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mTG-treated 33-mer were used at 9.48 nmol/mL, 3.16 nmol/mL, 1.05
nmol/mL, 0.35 nmol/mL, and 0.12 nmol/mL. mTG- and tTG-mTG-
treated DQ2.5-glia-α1a peptide or DQ2.5-glia-α2 peptide were used at
28.43 nmol/mL, 9.48 nmol/mL, 3.16 nmol/mL, 1.05 nmol/mL, or 0.35
nmol/mL. mTG- and tTG-mTG-treated gliadin was used at 20 μg/mL.
Both native and deamidated versions of DQ2.5-glia-α1a, DQ2.5-glia-α2,
and 33-mer peptides were used as controls. After 48 h at 37 °C, 0.5 μCi
of 3H-thymidine/well was added to the cultures and the cells were
harvested 18 h later. 3H-thymidine incorporation in the T-cell DNAwas
determined with a liquid scintillation counter (1205 Betaplate Liquid
Scintillation Counter) and results are expressed as the mean counts per
minute (c.p.m.).
Statistical Analysis. Statistical analyses were performed with
GraphPad Prism 7 software. Values are presented as the mean ±
standard deviation (SD) (n ≥ 3).
Figure 2. Identification of transamidated sites induced by mTG using LTQ-FT Ultra. (A) Observed fragment of DQ2.5-glia-α1a before treatment
(upper spectrum) and after treatment with mTG in the presence of Lys (lower spectrum); predicted fragment ion masses are given in the table with
identified ions illustrating transamidation shown in boxes. (B) Observed fragment of DQ2.5-glia-α2 before treatment (upper spectrum) and after
treatment with mTG in the presence of Lys (lower spectrum); predicted fragment ion masses are given in the table with identified ions illustrating
transamidation shown in boxes. Arrows indicate the shift in Da due to transamidation.
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Figure 3. Reactivity pattern of glia-α1and glia-α2-specific-T-cell clones to DQ2.5-glia-α1a, DQ2.5-glia-α2, 33-mer, gliadin, and their mTG-treated
forms. (A) Reactivity pattern of glia-α1-specific T-cell clone S2 and L5107 to DQ2.5-glia-α1a and its modified products (5 concentrations tested in each
group). (B) Reactivity pattern of glia-α2-specific T-cell clones S16 and D1 to DQ2.5-glia-α2 and its modified products (5 concentrations tested with S16
and only the highest concentration with D1). (C) Reactivity pattern of glia-α1-specific T-cell clones S2, and L5107 to 33-mer and its modified products
(5 concentrations tested in each group). (D) Reactivity pattern of glia-α2-specific T-cell clones S16 and D1 to 33-mer and its modified products (5
concentrations tested with S16 and only the highest concentration with D1). (E) Reactivity pattern of glia-α1-specific T-cell clones L6 and L10 to
DQ2.5-glia-α1a, 33-mer and their modified products (only the highest concentration tested). (F) Reactivity pattern of glia-α2-specific T-cell clones
101136 and L3-13 to DQ2.5-glia-α2, 33-mer and their modified products (only the highest concentration tested). (G) Reactivity pattern of glia-α1-
specific T-cell clones to gliadin protein and its modified products (only the highest concentration tested). (H) Reactivity pattern of glia-α2-specific T-
cell clones to gliadin protein and its modified products (only the highest concentration tested). PC, deamidated peptides as positive control; NC, native
peptides as negative control. Relative response: CPM of T cell clone caused by peptide/that of caused by deamidated peptide (positive control).
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■ RESULTS
Effect of pH and Concentration of Acyl-Acceptor
Molecule on Modification of Gliadin Peptides by mTG.
To achieve optimal modification of gliadin peptides by mTG, we
first determined the effect of pH and the concentration of the
acyl-acceptor molecule in two separate experiments. To
determine the effect of pH we incubated the 33-mer α-gliadin
peptide, known to contain three glutamine residues that can be
targeted by transglutaminases, with mTG and a molar excess of
Lys and HA at pH 6.0, pH 7.0, or pH 8.0. The MALDI-TOF
analysis of the end product demonstrate that at all three pH
values this resulted in shifts in molecular mass of 387 Da in the
case of Lys (Figure 1A) and 48 Da in the case of HA (Figure 1B),
indicative of the addition of three Lys and three HA molecules,
respectively. Moreover, the modification was highly efficient as
more than 99% of the 33-mer peptide was modified. Similarly,
incubation of the 33-mer peptide with mTG and the acyl
acceptor GEE also resulted in near complete modification at
every pH tested as demonstrated by a shift of 258 Da in the mass
of the peptide, corresponding to the addition of three GEE
molecules (data not shown). Also, similar results were obtained
with both the DQ2.5-glia-α1a (Supplementary Figure 1A−C)
and DQ2.5-glia-α2 peptides (Supplementary Figure 1E−G).
Together these results demonstrate that the pH did not have a
major impact on the transamidation reaction with any of the
three acyl-acceptor molecules.
To determine the effect of the concentration of the acyl-
acceptor molecule on the transamidation reaction, the 33-mer α-
gliadin peptide was incubated with mTG in the presence of 5
different concentrations of GEE. The MALDI-TOF analysis of
the end products demonstrate that at low concentrations of GEE
(0.16 and 0.63 μmol/mL) the modification was incomplete with
either one, two, or three additions of the acyl-acceptor molecules
to the gliadin peptide (Figure 1C). In contrast, at higher
concentrations (2.50, 10, and 40 μmol/mL) more than 99% of
the 33-mer was modified at three sites (Figure 1C). To ensure
(near) complete modification of the gliadin peptides, we chose to
use 40 μmol/mL acyl-acceptor concentrations for all further
experiments.
In contrast, the pH did influence mTG-mediated deamidation
(Supplementary Figure 1D,H). In line with previous results,22,31
the deamidation activity of mTG was maximal at pH 6.0 and
lower at neutral and basic pH.
Next we determined the mTG mediated modification of the
DQ2.5-glia-α1a, DQ2.5-glia-α2, and 33-mer peptides with three
distinct acyl-acceptor molecules, Lys, GEE, and HA under the
optimal conditions determined above. The MALDI-TOF
analysis indicated that the 33-mer peptide shifted 387, 258,
and 48 Da upon modification with Lys, GEE, and HA,
respectively, corresponding to the addition of three Lys, GEE,
and HA, respectively (Figure 1D). Similarly, the modification of
the DQ2.5-glia-α1a (Figure 1E) and DQ2.5-glia-α2 (Figure 1F)
peptides resulted in shifts of 129, 86, and 16Da, corresponding to
the addition of a single Lys, GEE, and HA group. In addition, we
observed that both lysine methyl ester and n-butylamine could be
similarly coupled to gliadin by mTG (Supplementary Figures 4
and 6). In all cases, the modification was nearly complete as
demonstrated by the disappearance of the unmodified peptide
and the sodium and potassium adducts thereof upon treatment
with mTG. Together this demonstrates that mTG can effectively
catalyze the transamidation reaction between all tested acyl-
acceptor molecules and glutamine residues in the three tested
gliadin peptides.
Identification of mTG Modified Glutamine Residues in
Gliadin Peptides. In the above experiments, we observed that a
single acyl-acceptor molecule was coupled to the DQ2.5-glia-α1a
and DQ2.5-glia-α2 peptides while three groups were added to
the 33-mer peptide, which indicates that the three tTG target
glutamines in these peptides are also modified bymTG. To verify
that this is indeed the case, the DQ2.5-glia-α1a and DQ2.5-glia-
α2 peptide were treated with mTG and acyl-acceptor molecules
and the end products were analyzed by FT-ICR. The resulting
MS/MS spectra of the peptides and fragments thereof indicated
that over 99% of the peptides were transamidated with all three
acyl-acceptor molecules (DQ2.5-glia-α1a, 99.7% (Lys), 99.6%
(GEE), and 99.5% (HA); DQ2.5-glia-α2:99.8% (Lys), 99.6%
(GEE), and 99.8% (HA)), confirming the results obtained with
the MALDI-TOF analysis.
For DQ2.5-glia-α1a (Figure 2A), theMS/MS spectra obtained
from the fragmentation of the native and Lys-modified peptides
reveal a series of b- and y-ions where the shift in m/z of 936 for
the b8-ion from the native peptide to 1065 in the modified
peptide indicates that the Lys modification occurred at the
glutamine residue of p8 in the peptide. This is confirmed by the
observed shift inm/z from 842 to 971 for the y7-ion (Figure 2A).
Similar results were obtained when GEE and HA were used as
acyl-acceptor molecules (Supplementary Figure 2A).
Similarly, for the DQ2.5-glia-α2 peptide the MS/MS spectra
indicate a shift in m/z from 808 to 937 for the b7-ion,
demonstrating that the Lys modification was at the glutamine at
p6 in the peptide (Figure 2B). Similar results were obtained with
the GEE and HA modifications (Supplementary Figure 2B).
Thus, mTG selectively modifies the gliadin peptides at a single
position which corresponds to Q8 in DQ2.5-glia-α1a and Q6 in
DQ2.5-glia-α2. Moreover, the transamidation was nearly
complete in all cases.
Abrogation of Immunogenic Properties of Gliadin
Peptides Is Both Acyl-Acceptor Molecule and T-Cell
Clone Dependent. To evaluate whether the treatment of
peptides with mTG and the three acyl-acceptor molecules
abrogated their immune stimulatory properties, four T-cell
clones specific for DQ2.5-glia-α1a and four T-cell clones specific
for DQ2.5-glia-α2 that have been previously isolated from
intestinal biopsies of patients were used. The TCR usage of all T-
cell clones was determined previously,4 and each T-cell clone
expressed a unique TCR (Supplementary Table 1).
For both the DQ2.5-glia-α1a and DQ2.5-glia-α2-specific T-
cell clones, the Lys and GEE modification of the DQ2.5-glia-α1a
and DQ2.5-glia-α2 peptides virtually abrogated the T-cell
response while modification with HA (Figure 3A−F,) and BL
(Supplementary Figure 6B) was hardly effective. Similarly, Lys
but not HA modification of the 33-mer peptide strongly reduced
the response of the T-cell clones while GEEmodification was less
effective for T-cell clone S2 (Figure 3C). To further investigate
the effectiveness of the modification with the acyl-acceptor
molecules, we tested two additional DQ2.5-glia-α1a and two
DQ2.5-glia-α2 specific T-cell clones. In line with the above
observations, the Lys modification was found to be highly
effective for the gliadin epitopes (Figure 3A,B and 3E,F), the 33-
mer (Figure 3C,D and 3E,F) and the gliadin protein (Figure
3G,H) while the HA modification was hardly effective. In
contrast, the GEEmodification was found to inhibit the response
of all DQ2.5-glia-α2 specific T-cell clones but proved ineffective
in the case of two of the DQ2.5-glia-α1a specific T-cell clones
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tested. Additionally, the three T-cell clones, L6, L10, and L3-13
also responded significantly to the nondeamidated native gliadin
peptides.
tTG-Catalyzed Hydrolysis of Transamidated Products
Can Generate Deamidated T-Cell Epitopes.Upon ingestion
of mTG transamidated gliadin, it could come into contact with
intestinal tTG. To determine the potential effect of this on the
immune stimulatory properties of the mTG treated gliadin, we
treated mTG transamidated DQ2.5-glia-α1a, DQ2.5-glia-α2, and
33-mer with tTG and determined the effect through mass
spectrometry. After incubation with tTG, a proportion of the
Lys-modified peptide was found to be delysinated, resulting in
deamidated gliadin (Figure 4A−C). Simultaneously, LME- and
BL-modified peptide were also partially reversed by tTG
(Supplementary Figures 4 and 6). Moreover, T-cell clones
specific for the DQ2.5-glia-α1a (Figure 5A,B) and DQ2.5-glia-α2
(Figure 5C,D and Supplementary Figure 6B) epitopes
responded to the tTG treated samples compared to the control
and mTG treated samples, indicating that tTG had indeed
reversed the transamidation of a proportion of the mTG treated
epitopes. Similarly, we observed that tTG can partially reverse
the mTG-mediated transamidation of gliadin protein (Figure
5E,F).
■ DISCUSSION
Wheat-based products are one of the most commonly consumed
foods worldwide. As wheat gluten is the causative agent in celiac
disease, this implies that a large number of food products are off
limit for patients suffering from this condition. While the
availability of bona fide gluten-free products has increased
significantly in recent years, these are not always a good
replacement for gluten-containing foods due to the special
properties of gluten proteins that confer superior baking
properties to wheat based-products.32 Also, an inappropriate
gluten-free diet can cause nutritional shortcomings, often lacks
sufficient fiber,33 and persists reduced digestibility.34 Detox-
ification of gluten proteins would be one approach to overcome
such shortcomings. The molecular basis for the toxic properties
of gluten is well established as T-cells specific for modified gluten
fragments bound to the disease-predisposing HLA-DQ2 and
-DQ8 molecules reside in the intestine of patients.1 Upon
activation, such T-cell secrete pro-inflammatory cytokines
leading to inflammation and remodelling of the intestinal
morphology. The modification of gluten is an enzymatic
conversion of particular glutamine residues in gluten fragments
into glutamic acid, introducing a negative charge that allows high-
affinity binding to either HLA-DQ2 or -DQ8. The enzyme
Figure 4. Analysis of DQ2.5-glia-α1a and DQ2.5-glia-α2 after mTG and tTG treatment byMALDI-TOF. (A)Mass spectrum of DQ2.5-glia-α1a (upper
panel), DQ2.5-glia-α1a after mTG transamidation with Lys (mTG-Lys, middle panel), and after tTG treatment of Lys transamidated DQ2.5-glia-α1a
(tTG-mTG-Lys, lower panel). (B) Mass spectrum of DQ2.5-glia-α2 (upper panel), DQ2.5-glia-α2 after mTG transamidation with Lys (mTG-Lys,
middle panel), and after tTG treatment of Lys transamidated DQ2.5-glia-α2 (tTG-mTG-Lys, lower panel). (C) Mass spectrum of 33-mer (upper
panel), 33-mer after mTG transamidation with Lys (mTG-Lys, middle panel), and after tTG treatment of Lys transamidated 33-mer (tTG-mTG-Lys,
lower panel). The deamidation of Q→ E would result in a 1 Da shift. Monoisotopic mass are shown throughout. Arrows indicate the shift in Da after
modification.
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involved, tTG, specifically modifies glutamine residues in QXP
sequences (where X can be any amino acid except proline) but
not in QP sequences, which results in highly selective
modification of particular glutamine residues only due to the
proline-rich nature of gluten proteins.11,27 Enzymatic modifica-
tion of these glutamine residues has therefore been proposed as
an approach to prohibit the conversion of glutamine to glutamic
acid by tTG. Indeed, enzymatic coupling of Lys to the tTG target
glutamines in gluten has been shown to diminish the
immunogenicity of gluten.16 In addition, mTG has also been
shown to effectively mediate this transamidation.16 However, a
systematic analysis of the effectiveness of such an approach with a
panel of well characterized gluten-specific T-cell clones from
patients is currently lacking. Moreover, the coupling of the
relatively large amino acid Lys to several glutamine residues in
gluten proteins may affect their unique properties. Therefore, in
the present study we have determined if smaller acyl-acceptor
molecule would be equally capable of reducing the immunogenic
properties of gluten proteins and peptides. Our results provide
detailed insight into the transamidation of gliadin peptides and
proteins by mTG and three distinct acyl-acceptor molecules. We
have used mass spectrometry to determine the extent and exact
location of the mTG mediated modifications and we have
exploited the availability of gliadin-specific T-cell clones to
monitor the impact of these modifications in detail. Finally, we
have investigated if tTG could revert the effect of mTG-mediated
transamidation.
Our results demonstrate that the DQ2.5-glia-α1a, DQ2.5-glia-
α2, and 33-mer peptides were almost completely transamidated
by mTG with all five acyl-acceptor molecules used, which
confirms and extends the previous observation that mTG has a
strong transamidation activity.22 Similarly, we observed that the
Figure 5. tTG can revert mTG-mediated transamidation. (A) Reactivity pattern of glia-α1-specific T-cell clone L5107 to DQ2.5-glia-α1a (left panel),
the 33-mer (right panel) before (NC) and after mTG transamidation with Lys (mTG-Lys) and after tTG treatment of mTG-Lys (tTG-mTG-Lys). (B)
Reactivity pattern of glia-α1-specific T-cell clones S2 and L6 to DQ2.5-glia-α1a, 33-mer, and their modified products. (C) Reactivity pattern of glia-α2-
specific T-cell clone S16 to DQ2.5-glia-α2 (left panel) and the 33-mer (right panel) before (NC) and after mTG transamidation with Lys (mTG-Lys)
and after tTG treatment of mTG-Lys (tTG-mTG-Lys). (D) Reactivity pattern of glia-α2-specific T-cell clones D1 and 101136 to DQ2.5-glia-α2, 33-
mer, and their modified products. (E) Reactivity pattern of glia-α1-specific T-cell clones to gliadin protein before (NC) and after mTG transamidation
with Lys (mTG-Lys) and after tTG treatment of mTG-Lys (tTG-mTG-Lys). Three different concentrations of lysine were used, 10, 40, and 160 mM as
indicated. (F) Reactivity pattern of glia-α2-specific T-cell clones to gliadin protein and its modified products.
Journal of Agricultural and Food Chemistry Article
DOI: 10.1021/acs.jafc.7b02557
J. Agric. Food Chem. 2017, 65, 7542−7552
7549
pH did not have a major impact on the transamidation reaction,
indicating that transamidation of gluten proteins by mTG would
be robust under a variety of conditions. However, in agreement
with previous observations22 mTG displayed pH-dependent
deamidation activity which wasmaximal at pH 6.0 andminimal at
pH 8.0. Thus, mTG mediated modification of gluten should
preferably be carried out at higher pH values to avoid the
deamidation of gluten which is known to increase immunoge-
nicity. Importantly, our results indicated that mTG targeted the
same glutamine residues that are modified by tTG in both the
DQ2.5-glia-α1a, DQ2.5-glia-α2, and in the 33-mer gliadin
peptide (Figure 2 and Supplementary Figure 2). Thus, the
transamidation of gluten by mTG can be used to prevent the
deamidation of gluten which enhances the binding of gluten
epitopes to HLA-DQ molecules. Our results are in contrast to a
recent study22 where two glutamine residues were transamidated
in the peptide QPFPQPQLPYPQPQ, encompassing both the
DQ2.5-glia-α1a and DQ2.5-glia-α2 epitopes. This may be due to
different reaction conditions such as the concentration of acyl-
acceptor molecules and reaction time employed.
We have used a panel of well characterized T-cell clones to
evaluate the effect of the transamidation of gliadin peptides and
proteins. While it is likely that abrogation of T-cell reactivity
against transamidated gliadin peptides results from impaired
binding to HLA-DQ, transamidation may also affect the
conformation of the gliadin peptide in HLA-DQ, a possibility
that cannot be inferred from the results with the T-cells.
Nonetheless, whatever the mechanism, abrogation of T-cell
stimulatory properties would render gluten safe for consumption
by celiac disease patients.
While the transamidation of the Q residues in the DQ2.5-glia-
α1a and DQ2.5-glia-α2 epitopes was nearly complete with all
three acyl-acceptor molecules, significant differences were found
with respect to the response of T-cell clones specific for these
epitopes. In agreement with previous results,16 the modification
with Lys drastically reduced the proliferation of all T-cell clones.
In contrast, the modification with GEE was similarly effective in
the case of DQ2.5-glia-α2-specific T-cell clones but less effective
for DQ2.5-glia-α1-specific T-cell clones. This may relate to the
featureless central region of the DQ2.5-glia-α1a peptide while
bound to HLA-DQ2.5,4 where the relatively small addition of the
GEE group may not affect the binding interface with the T-cell
receptor. Strikingly, the modification with HA was largely
ineffective even though this acyl-acceptor molecule was coupled
as efficiently as the Lys and GEE groups. Presumably, the HA-
modification had little effect on the binding of the modified
peptides while that with GEE and Lys does. In this respect it is
important to note that several of the T-cell clones also responded
significantly to the nondeamidated native gliadin peptides, in line
with previous results indicating that deamidation of gluten
peptides is not always a prerequisite for T-cell recognition.29,30
As such, transamidation of gliadin would not only prevent
deamidation but would also eliminate T-cell responses to native
gliadin peptides. Importantly, mTG-transamidation of gliadin
also abolished the T-cell stimulatory properties. However, as not
all T-cell clones tested were equally affected by the mTG
mediated transamidation, this may imply that the effect of mTG
mediated transamidation can vary from patient to patient
depending on the expressed T-cell receptor repertoire.
Finally, we demonstrate that guinea pig derived tTG can
partially undo the mTG mediated transamidation reaction as we
observed T-cell responses to mTG-transamidated gliadin
peptides that were subsequently treated with tTG, a result
consistent with a previous observation that tTG can hydrolyze
iso-peptide bonds.35 While evidence for hydrolyzation of the iso-
peptide bond was already apparent after 1 h, it is of note that
most of the transamidated peptide was still intact even after 16 h
incubation. Moreover, it is unclear whether human tTG can
hydrolyze iso-peptide bonds as this is distinct from guinea pig
tTG which could affect catalytic activity and substrate
specificity.36,37 Finally, in future studies it may be worthwhile
to combine mTG mediated transamidation with other
approaches to reduce the immunogenicity of gluten.38,39
In conclusion, our results confirm previous results that mTG
can effectively transamidate gliadin peptides and gluten proteins.
We demonstrate that transamidation with Lys is most effective to
abrogate the immune stimulatory properties of gluten while the
coupling of smaller acyl-acceptor molecule is less (GEE) effective
or mostly ineffective (HA). At present transamidation with lysine
is thus the only available option to eliminate gluten toxicity. In
this respect, it is important to note that food grade lysine is
readily available on the market, potentially enabling the large
scale production of transamidated gluten for incorpotation in
food products. However, our results on the reversibility of the
mTG mediated transamidation indicate that this may also occur
in vivo. Thus, additional studies are required to test the impact of
these modifications on gluten baking properties and in vivo
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